Critical review of cancer risk associated with angiotensin receptor blocker therapy
Grégoire Wuerzner1,3, Michel Burnier1, Bernard Waeber2,3
1Service of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, 2Division of Clinical Pathophysiology, Centre Hospitalier Universitaire Vaudois, 3Clinical Research Centre, Unil/Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Abstract: The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk.
Keywords: hypertension, cancer, angiotensin receptor blocker, meta-analyses
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.